HCPCS drug code · CMS crosswalk
Cyclophosphamide J-Code / HCPCS Code
In short
CMS assigns Cyclophosphamide NDCs to 7 HCPCS codes: J8530 (per 25 mg), J9071 (per 5 mg), J9072 (per 5 mg), J9073 (per 5 mg), J9074 (per 5 mg), J9075 (per 5 mg), J9076 (per 5 mg). Which one applies depends on the product; the table lists each NDC with its code.
J8530 code detailsJ9071 code detailsJ9072 code detailsJ9073 code detailsJ9074 code detailsJ9075 code detailsJ9076 code details
Reference
- J8530
- Cyclophosphamide; oral, 25 mgBilling unit: 25 mg
- J9071
- Injection, cyclophosphamide (auromedics), 5 mgBilling unit: 5 mg
- J9072
- Injection, cyclophosphamide (frindovyx), 5 mgBilling unit: 5 mg
- J9073
- Injection, cyclophosphamide (dr. reddy's), 5 mgBilling unit: 5 mg
- J9074
- Injection, cyclophosphamide (sandoz), 5 mgBilling unit: 5 mg
- J9075
- Injection, cyclophosphamide, not otherwise specified, 5 mgBilling unit: 5 mg
- J9076
- Injection, cyclophosphamide (baxter), 5 mgBilling unit: 5 mg
- Labelers
- Amneal Pharmaceuticals, LLC; Athenex Pharmaceutical Division, LLC; Avyxa Pharma, LLC; Baxter Healthcare Corporation; BluePoint Laboratories; Bluepoint Laboratories; Cipla USA, Inc.; Civica, Inc.and 9 more
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Cyclophosphamide units and claim line
Enter the dose given to get the J8530 units and the NDC line for the CMS-1500 and the 837P. This builds the J8530 line; use the code page for J9071, J9072, J9073, J9074, J9075, J9076.
Enter the dose given to build the claim line.
Cyclophosphamide NDCs and billing units
From CMS’s ASP NDC–HCPCS crosswalk, effective October 1, 2026 through December 31, 2026. Billing units per package are CMS’s figures for the code’s unit.
| NDC (11-digit) | HCPCS | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| 00054-0382-25 | J8530 | Hikma Pharmaceuticals USA Inc. | 100 | 100 |
| 00054-0383-25 | J8530 | Hikma Pharmaceuticals USA Inc. | 100 | 200 |
| 10019-0984-01 | J8530 | Baxter Healthcare Corporation | 100 | 200 |
| 69097-0516-07 | J8530 | Cipla USA, Inc. | 100 | 100 |
| 69097-0517-07 | J8530 | Cipla USA, Inc. | 100 | 200 |
| 55150-0270-99 | J9071 | Eugia US LLC | 2.5 | 100 |
| 55150-0271-99 | J9071 | Eugia US LLC | 5 | 200 |
| 55150-0272-01 | J9071 | Eugia US LLC | 10 | 400 |
| 83831-0116-01 | J9072 | Avyxa Pharma, LLC | 1 | 100 |
| 83831-0117-02 | J9072 | Avyxa Pharma, LLC | 1 | 200 |
| 83831-0118-04 | J9072 | Avyxa Pharma, LLC | 1 | 400 |
| 68001-0564-22 | J9073 | BluePoint Laboratories | 5 | 200 |
| 68001-0565-28 | J9073 | BluePoint Laboratories | 10 | 400 |
| 70860-0218-10 | J9073 | Athenex Pharmaceutical Division, LLC | 10 | 400 |
| 75907-0189-35 | J9073 | Dr. Reddy's Laboratories Inc. | 10 | 400 |
| 75907-0190-07 | J9073 | Dr. Reddy's Laboratories Inc. | 5 | 200 |
| 75907-0191-02 | J9073 | Dr. Reddy's Laboratories Inc. | 2.5 | 100 |
| 00781-3528-10 | J9074 | Sandoz Inc. | 5 | 100 |
| 00781-3529-10 | J9074 | Sandoz Inc. | 10 | 200 |
| 00781-3530-10 | J9074 | Sandoz Inc. | 20 | 400 |
| 00781-3233-94 | J9075 | Sandoz Inc. | 1 | 100 |
| 00781-3244-94 | J9075 | Sandoz Inc. | 1 | 200 |
| 00781-3255-94 | J9075 | Sandoz Inc. | 1 | 400 |
| 10019-0938-01 | J9075 | Baxter Healthcare Corporation | 1 | 100 |
| 10019-0939-01 | J9075 | Baxter Healthcare Corporation | 1 | 200 |
| 10019-0942-01 | J9075 | Baxter Healthcare Corporation | 1 | 400 |
| 10019-0943-01 | J9075 | Baxter Healthcare Corporation | 1 | 100 |
| 10019-0944-01 | J9075 | Baxter Healthcare Corporation | 1 | 200 |
| 10019-0945-01 | J9075 | Baxter Healthcare Corporation | 1 | 400 |
| 10019-0955-01 | J9075 | Baxter Healthcare Corporation | 1 | 100 |
| 10019-0956-01 | J9075 | Baxter Healthcare Corporation | 1 | 200 |
| 10019-0957-01 | J9075 | Baxter Healthcare Corporation | 1 | 400 |
| 16714-0857-01 | J9075 | Northstar RxLLC | 1 | 200 |
| 16714-0858-01 | J9075 | Northstar RxLLC | 1 | 400 |
| 16714-0859-01 | J9075 | Northstar RxLLC | 1 | 100 |
| 25021-0247-50 | J9075 | Sagent Pharmaceuticals | 1 | 100 |
| 25021-0248-51 | J9075 | Sagent Pharmaceuticals | 1 | 200 |
| 25021-0249-51 | J9075 | Sagent Pharmaceuticals | 1 | 400 |
| 39822-0250-01 | J9075 | XGen Pharmaceuticals DJB, Inc. | 1 | 100 |
| 39822-0255-01 | J9075 | XGen Pharmaceuticals DJB, Inc. | 1 | 200 |
| 39822-0260-01 | J9075 | XGen Pharmaceuticals DJB, Inc. | 1 | 400 |
| 65219-0131-20 | J9075 | FreseniUS Kabi USA, LLC | 1 | 200 |
| 65219-0133-20 | J9075 | FreseniUS Kabi USA, LLC | 1 | 400 |
| 65219-0135-20 | J9075 | FreseniUS Kabi USA, LLC | 1 | 100 |
| 68001-0442-26 | J9075 | BluePoint Laboratories | 1 | 100 |
| 68001-0443-27 | J9075 | BluePoint Laboratories | 1 | 200 |
| 68001-0444-32 | J9075 | BluePoint Laboratories | 1 | 400 |
| 68001-0694-27 | J9075 | Bluepoint Laboratories | 1 | 100 |
| 68001-0695-32 | J9075 | Bluepoint Laboratories | 1 | 200 |
| 68001-0696-32 | J9075 | BluePoint Laboratories | 1 | 400 |
| 70121-1238-01 | J9075 | Amneal Pharmaceuticals, LLC | 1 | 100 |
| 70121-1239-01 | J9075 | Amneal Pharmaceuticals, LLC | 1 | 200 |
| 70121-1240-01 | J9075 | Amneal Pharmaceuticals, LLC | 1 | 400 |
| 72572-0083-01 | J9075 | Civica, Inc. | 1 | 400 |
| 72572-0085-01 | J9075 | Civica, Inc. | 1 | 200 |
| 72572-0087-01 | J9075 | Civica, Inc. | 1 | 100 |
| 72603-0104-01 | J9075 | Northstar RxLLC | 1 | 100 |
| 72603-0326-01 | J9075 | Northstar RxLLC | 1 | 200 |
| 81298-8110-01 | J9075 | Long Grove Pharmaceuticals, LLC | 1 | 100 |
| 81298-8112-01 | J9075 | Long Grove Pharmaceuticals, LLC | 1 | 200 |
| 81298-8114-01 | J9075 | Long Grove Pharmaceuticals, LLC | 1 | 400 |
| 00338-9777-01 | J9076 | Baxter Healthcare Corporation | 2.5 | 100 |
| 00338-9779-01 | J9076 | Baxter Healthcare Corporation | 5 | 200 |
Cyclophosphamide: common questions
- What is the J-code for Cyclophosphamide?
- CMS assigns Cyclophosphamide NDCs to 7 HCPCS codes: J8530 (per 25 mg), J9071 (per 5 mg), J9072 (per 5 mg), J9073 (per 5 mg), J9074 (per 5 mg), J9075 (per 5 mg), J9076 (per 5 mg). Which one applies depends on the product; the table lists each NDC with its code.
- How many J8530 billing units are in a package of Cyclophosphamide?
- CMS lists 100 to 200 billing units per package, depending on the NDC, where one unit is 25 mg. Units to report are based on the dose given, not the package.
- How many J9071 billing units are in a package of Cyclophosphamide?
- CMS lists 100 to 400 billing units per package, depending on the NDC, where one unit is 5 mg. Units to report are based on the dose given, not the package.
- How many J9072 billing units are in a package of Cyclophosphamide?
- CMS lists 100 to 400 billing units per package, depending on the NDC, where one unit is 5 mg. Units to report are based on the dose given, not the package.
- How many J9073 billing units are in a package of Cyclophosphamide?
- CMS lists 100 to 400 billing units per package, depending on the NDC, where one unit is 5 mg. Units to report are based on the dose given, not the package.
- How many J9074 billing units are in a package of Cyclophosphamide?
- CMS lists 100 to 400 billing units per package, depending on the NDC, where one unit is 5 mg. Units to report are based on the dose given, not the package.
- How many J9075 billing units are in a package of Cyclophosphamide?
- CMS lists 100 to 400 billing units per package, depending on the NDC, where one unit is 5 mg. Units to report are based on the dose given, not the package.
- How many J9076 billing units are in a package of Cyclophosphamide?
- CMS lists 100 to 200 billing units per package, depending on the NDC, where one unit is 5 mg. Units to report are based on the dose given, not the package.
- Is J8530 a CPT code?
- No. J8530 is a HCPCS Level II code from CMS for the drug itself. Giving it, for example by injection or infusion, is usually reported with a separate CPT administration code.